Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EBT (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of EBT data on record, last reported at -$4.7 million in Q3 2025.

  • For Q3 2025, EBT fell 5.82% year-over-year to -$4.7 million; the TTM value through Sep 2025 reached -$18.1 million, up 16.26%, while the annual FY2024 figure was -$19.9 million, 11.58% up from the prior year.
  • EBT reached -$4.7 million in Q3 2025 per GANX's latest filing, up from -$5.7 million in the prior quarter.
  • Across five years, EBT topped out at $12.7 million in Q4 2022 and bottomed at -$8.1 million in Q2 2024.
  • Average EBT over 5 years is -$3.3 million, with a median of -$4.6 million recorded in 2022.
  • The widest YoY moves for EBT: up 238.61% in 2021, down 559.39% in 2021.
  • A 5-year view of EBT shows it stood at $4.4 million in 2021, then surged by 191.42% to $12.7 million in 2022, then tumbled by 139.22% to -$5.0 million in 2023, then surged by 34.72% to -$3.3 million in 2024, then plummeted by 45.09% to -$4.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$4.7 million in Q3 2025, -$5.7 million in Q2 2025, and -$4.4 million in Q1 2025.